Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Share-based Compensation: 2011-2024

Historic Share-based Compensation for Tg Therapeutics (TGTX) over the last 14 years, with Dec 2024 value amounting to $42.5 million.

  • Tg Therapeutics' Share-based Compensation rose 49.88% to $17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.0 million, marking a year-over-year increase of 52.49%. This contributed to the annual value of $42.5 million for FY2024, which is 12.15% up from last year.
  • Per Tg Therapeutics' latest filing, its Share-based Compensation stood at $42.5 million for FY2024, which was up 12.15% from $37.9 million recorded in FY2023.
  • Tg Therapeutics' Share-based Compensation's 5-year high stood at $80.3 million during FY2020, with a 5-year trough of $37.9 million in FY2023.
  • Over the past 3 years, Tg Therapeutics' median Share-based Compensation value was $42.5 million (recorded in 2024), while the average stood at $41.7 million.
  • As far as peak fluctuations go, Tg Therapeutics' Share-based Compensation surged by 608.33% in 2020, and later decreased by 27.14% in 2022.
  • Yearly analysis of 5 years shows Tg Therapeutics' Share-based Compensation stood at $80.3 million in 2020, then fell by 23.65% to $61.3 million in 2021, then fell by 27.14% to $44.7 million in 2022, then fell by 15.07% to $37.9 million in 2023, then rose by 12.15% to $42.5 million in 2024.